Insider Selling: Roivant Sciences (NASDAQ:ROIV) Director Sells 800,000 Shares of Stock

Posted by Brenda Bartman on Jun 30th, 2026

Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) Director Daniel Allen Gold sold 800,000 shares of the firm’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $34.55, for a total transaction of $27,640,000.00. Following the completion of the transaction, the director directly owned 13,701,546 shares of the company’s stock, valued at approximately $473,388,414.30. The trade was a 5.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Daniel Allen Gold also recently made the following trade(s):

On Tuesday, June 30th, Daniel Allen Gold sold 12,380 shares of Roivant Sciences stock. The stock was sold at an average price of $35.28, for a total value of $436,766.40.
On Friday, June 26th, Daniel Allen Gold sold 625,783 shares of Roivant Sciences stock. The shares were sold at an average price of $34.00, for a total value of $21,276,622.00.

Roivant Sciences Trading Up 1.9%

NASDAQ:ROIV traded up $0.66 during midday trading on Tuesday, hitting $35.39. 6,160,114 shares of the company were exchanged, compared to its average volume of 5,917,255. The company has a fifty day simple moving average of $29.88 and a 200 day simple moving average of $27.02. The company has a market capitalization of $25.45 billion, a PE ratio of -58.98 and a beta of 1.13. Roivant Sciences Ltd. has a fifty-two week low of $10.70 and a fifty-two week high of $35.90.

Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its quarterly earnings data on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.57. Roivant Sciences had a negative net margin of 3,629.19% and a negative return on equity of 20.54%. The company had revenue of $2.52 million for the quarter, compared to analyst estimates of $3.41 million. During the same period in the previous year, the business posted ($0.29) earnings per share. As a group, equities research analysts expect that Roivant Sciences Ltd. will post -1.83 EPS for the current year.

Hedge Funds Weigh In On Roivant Sciences

Hedge funds have recently added to or reduced their stakes in the business. Pacer Advisors Inc. raised its position in Roivant Sciences by 37.1% during the first quarter. Pacer Advisors Inc. now owns 96,303 shares of the company’s stock worth $2,668,000 after acquiring an additional 26,044 shares during the last quarter. Empowered Funds LLC grew its position in shares of Roivant Sciences by 1,468.5% in the first quarter. Empowered Funds LLC now owns 285,915 shares of the company’s stock valued at $7,920,000 after purchasing an additional 267,686 shares during the last quarter. Seven Fleet Capital Management LP purchased a new position in shares of Roivant Sciences during the 1st quarter worth approximately $3,550,000. Parallel Advisors LLC increased its stake in shares of Roivant Sciences by 33.7% during the 1st quarter. Parallel Advisors LLC now owns 2,065 shares of the company’s stock worth $57,000 after purchasing an additional 520 shares in the last quarter. Finally, Perceptive Advisors LLC raised its position in shares of Roivant Sciences by 3.8% during the 1st quarter. Perceptive Advisors LLC now owns 8,285,461 shares of the company’s stock worth $229,507,000 after purchasing an additional 300,000 shares during the last quarter. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on ROIV shares. TD Cowen upped their price target on shares of Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a research note on Thursday, May 21st. Leerink Partners set a $42.00 target price on shares of Roivant Sciences in a report on Thursday, May 21st. Weiss Ratings lowered Roivant Sciences from a “sell (d)” rating to a “sell (d-)” rating in a research note on Friday, May 22nd. Guggenheim upped their price target on Roivant Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, May 26th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of Roivant Sciences in a research note on Tuesday, March 3rd. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.59.

View Our Latest Analysis on Roivant Sciences

Roivant Sciences Company Profile

(Get Free Report)

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.